Company Overview and News

0
Dentsply Sirona to Host Second Quarter 2018 Conference Call on August 7th

2018-07-20 globenewswire
YORK, Pa., July 20, 2018 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (NASDAQ:XRAY), The Dental Solutions Company™, today announced that the Company will host an investor conference call and live webcast on Tuesday, August 7, 2018 at 8:30 am ET and send out an earnings press release earlier that morning. A presentation related to the call will be available on www.dentsplysirona.com in the Investors section.
XRAY

2
UPDATE 2-Danaher's dental spinoff plan, profit beat push shares higher

2018-07-19 reuters
(Reuters) - Danaher Corp (DHR.N) said on Thursday it would spin off its dental unit into a publicly traded company, as the medical equipment maker seeks to revitalize a struggling business.
MTSI FTV.PRA FTV XRAY DHR

0
UPDATE 1-Danaher to spin off dental unit; to complete in 2019

2018-07-19 reuters
July 19 (Reuters) - Medical equipment maker Danaher Corp said on Thursday that it plans to spin off its dental business, which had annual sales of nearly $3 billion in 2017, into a publicly traded company.
MTSI XRAY DHR

4
Henry Schein's JV With Internet Brands to Boost Dental Arm

2018-07-03 zacks
Henry Schein, Inc. (HSIC - Free Report) recently announced that it has completed the earlier-announced joint venture (JV) with Internet Brands, a KKR portfolio company, in a bid to fortify its Dental business. The companies have named the joint venture Henry Schein One. However, financial terms of the deal have been kept under wraps.
XRAY SYK ABMD HSIC GHDX

0
Dentsply Sirona Declares Quarterly Cash Dividend

2018-06-26 globenewswire
YORK, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (NASDAQ:XRAY), The Dental Solutions CompanyTM, announced that its Board of Directors declared a quarterly cash dividend of $0.0875 per share of common stock, an indicated annual rate of $0.35 per share. The dividend is payable on October 12, 2018 to holders of record on September 28, 2018.
XRAY

994
20 Massively Underpriced Stocks Wall Street Expects to Soar

2018-06-25 investorplace
Wall Street doesn’t always get it right, but analysts’ track record is better than some skeptics suggest. And when the Street as a whole is arguing for big upside, investors should at least consider what those analysts have to say.
LRCX ARNC.PR HA TEVA ARNC.PRB AA.PRB MFIN GTN.A CMN AMAT HMNY CELG QUAD AA TRBAB MHO FOX SBNY AMC HXSCF AAL TMUS TRBNW VRX CMD ARNC MDT GTN MHK FOXA AMWD SBGI HXSCL MFINL OLED LEN MDCO TEVVF NFLX CXO WGO CHTR AAI RSPP AAPL DAL DIS LUV DISH SBNYW CMCSA THO NYTAB S XRAY TEVJF MU AA.PR DHI TRCO

0
PanHellenic Awards Ceremony & Gala Breaks Record with $260,000 in Scholarships

2018-06-22 thenationalherald
The Scholarship recipients led the dancing at the PanHellenic Gala. Photo: Sofia Spentzas - Spiral Art Design
XRAY

3
XRAY / DENTSPLY SIRONA Inc. FORM 11-K

2018-06-21 sec.gov
Document UNITED STATES
XRAY

29
Here's Why You Should Hold Onto DENTSPLY SIRONA Stock Now

2018-06-20 zacks
With a market capitalization of approximately $10.17 billion, DENTSPLY SIRONA (XRAY - Free Report) reported in-line earnings in the trailing three quarters. However, the company faces margin threats and foreign exchange headwinds.
XRAY SYK ABMD GHDX

25
IMF June Buys: The 16 Stocks Added To My Fund

2018-06-11 seekingalpha
Ian's Million Fund "IMF" is a real-money portfolio that I've written about monthly since January 2016 here at Seeking Alpha. The portfolio is a largely buy-and-hold group of ~100 stocks. Each month, I buy 10-25 of the most compelling stocks available at then-current prices, deploying $1,000 of my capital plus accumulated dividends. If things go according to plan, this portfolio, began when I was 27, will hit one million dollars in equity in 2041 at age 52.
DESP ENB HRL TFSL BUD NYCB.PRA XRAY WBA NYCB.PRU NYCB AHBIF ENB

1
DENTSPLY (XRAY) Down 11.8% Since Earnings Report: Can It Rebound?

2018-06-05 zacks
A month has gone by since the last earnings report for DENTSPLY SIRONA Inc. (XRAY - Free Report) . Shares have lost about 11.8% in that time frame.
XRAY

38
2018 Q1 Hedge Fund Resource – JHL, BRK, Druck, Ackman, Loeb, Einhorn, Short Pitches, Sohn ConferenceS, Ivey, Gator, Cooper, Shortselling, ValueAct, Top Emerging Managers And More – ValueWalk Premium

2018-06-05 valuewalkpremium
Broad Run Investment Management describe why in a quarter in which “the prospect of rising interest rates and increasing geopolitical tensions challenged Goldilocks economic forecasts,” they saw opportunity to add to existing core positions American Woodmark and Carmax. 5/24
BRK.A XRAY AMWD

39
Align Technology Reported a 52-Week High on May 29

2018-06-01 marketrealist
Align Technology (ALGN) hosted its 2018 Investor Day on May 23. On the day, the company provided an updated long-term revenue growth target range and reaffirmed its Q2 2018 and 2018 guidances. It also discussed its key growth drivers, its digital platform, and its recently announced products, and it presented its Invisalign palatal expander for the first time.
ALGN XRAY ZBH HSIC

39
Word on the Street: Recommendations and Target Prices on ALGN

2018-06-01 marketrealist
Align Technology (ALGN) has reported a strong stock performance recently, with its stock price reaching a 52-week high on May 29.
ALGN XRAY ZBH HSIC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to XRAY / DENTSPLY SIRONA Inc. on message board site Silicon Investor.

XRAY - Undiscovered Gem XRMD - XRAYMEDIA.COM INC
Xraymedia/Ebidd
CUSIP: 24906P109